← ANALYST RATINGS · TIPRANKS
CareDx (CDNA): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy1 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $67.67, the highest $74.00, the lowest $64.00. The average is +5.7% from the last price of $64.00.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $64.00 → $73.00+14.1% | Buy | +14.1% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $63.00 → $70.00+11.1% | Hold | +9.4% | Downgrade | 07.10.26on TipRanks 05:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $62.00 → $71.00+14.5% | Buy | +10.9% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $68.00 → $71.00+4.4% | Buy | +10.9% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $64.00 → $74.00+15.6% | Buy | +15.6% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $61.00 → $72.00+18.0% | Buy | +12.5% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $60.00 → $74.00+23.3% | Buy | +15.6% | Reiterated | 24.09.26on TipRanks 07:15 | +13.1%next day +3.2% · 5 days +8.3% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $65.00 | Buy | +1.6% | Initiated | 02.09.26on TipRanks 06:00 | +0.8%next day −0.5% · 5 days +1.8% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | $35.00 → $64.00+82.9% | Buy | 0.0% | Upgrade | 03.08.26on TipRanks 07:15 | +8.0%next day −3.4% · 5 days −3.7% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Hold | — | Assigned | 03.08.26on TipRanks 04:55 | +8.0%next day −3.4% · 5 days −3.7% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $46.00 | Hold | −28.1% | Reiterated | 31.07.26on TipRanks 06:50 | +14.0%next day +8.0% · 5 days +3.3% | ↗ |
| Unknown Analyst | Wells Fargo | $21.00 | Hold | −67.2% | Reiterated | 29.07.26on TipRanks Jul 31 01:06 | +0.6%next day +5.9% · 5 days +23.0% | ↗ |
| Unknown Analyst | Stephens | $28.00 | Buy | −56.2% | Reiterated | 29.04.26on TipRanks 09:20 | −5.1%next day −0.9% · 5 days −2.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering CareDx
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $54.00 at a price of $65.00 (−16.9%); now: $54.00 at $64.00 (−15.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 3 | 5 | 4 |
| Hold | 6 | 8 | 5 | 5 | 4 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.26 (from $0.24 to $0.27). Last quarter: $0.37.
Sales
Next quarter’s sales estimate — $122M (from $121M to $124M). Last quarter: $132M.
Best top-analyst consensus in the sector · Healthcare
About CareDx
- CEO: John Walter Hanna Jr.
- Employees: 763
- 8000 Marina Boulevard, Brisbane, CA, 94005, US
- www.caredx.com
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss po
Data from the stock’s TipRanks forecast page, read 73 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗